2516-37-2

Basic information

• Product Name: 2-BROMO-6-NITROBENZOTHIAZOLE
• Synonyms: 2-BROMO-6-NITRO-1,3-BENZOTHIAZOLE;2-BROMO-6-NITROBENZOTHIAZOLE;2-bromo-6-nitrobenzo[d]thiazole;6-Nitro-2-bromobenzothiazole
• CAS NO: 2516-37-2
• Molecular Formula: C₇H₃BrN₂O₂S
• Molecular Weight: 259.08
• Mol File: 2516-37-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 206-207
• Boiling Point: 393.1 °C at 760 mmHg
• Flash Point: 191.6 °C
• Appearance: /
• Density: 1.929
• Vapor Pressure: 4.93E-06mmHg at 25°C
• Refractive Index: 1.751
• PKA: -2.40±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-6-NITROBENZOTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-6-NITROBENZOTHIAZOLE(2516-37-2)
• EPA Substance Registry System: 2-BROMO-6-NITROBENZOTHIAZOLE(2516-37-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 2516-37-2(Hazardous Substances Data)

Usage

General Description

2-BROMO-6-NITROBENZOTHIAZOLE is a chemical compound with the molecular formula C7H4BrN3O2S. It is a yellowish crystalline powder that is commonly used in the synthesis of pharmaceuticals and agrochemicals. 2-BROMO-6-NITROBENZOTHIAZOLE has been found to exhibit antimicrobial and antifungal properties, making it useful in the development of medicinal and agricultural products. 2-BROMO-6-NITROBENZOTHIAZOLE is also used as an intermediate in the production of dyes, pigments, and other organic compounds. However, it is important to handle this chemical with care, as it is known to be harmful if swallowed, inhaled, or brought into contact with the skin.

InChI:InChI=1/C7H3BrN2O2S/c8-7-9-5-2-1-4(10(11)12)3-6(5)13-7/h1-3H

Upstream product

• 6285-57-0 2-amino-6-nitrobenzothiazole 

Downstream Products

• 115104-90-0 6-nitro-N-phenylbenzo[d]thiazol-2-amine 
• 6392-97-8 2-phenylbenzo[d]thiazole-6-amine 
• 1448780-09-3 2-(4'-amino-3-nitrophenyl)-6-nitrobenzothiazole 
• 53544-74-4 2-(4'-nitrophenyl)-6-nitrobenzothiazole 
• 488722-59-4 4-(6-nitrobenzo[d]thiazol-2-yl)benzenamine 
• 1227077-04-4 C₁₅H₈N₂O₂S 
• 1416718-14-3 (S)-tert-butyl 2-(2-(4-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl)benzo[d]thiazol-6-ylcarbamoylcarbamoyl)pyrrolidine-1-carboxylate 
• 1416718-16-5 methyl (S)-1-((S)-2-(5-(4-(6-(3-((S)-1-((R)-2-(dimethylamino)-2-phenylacetyl)pyrrolidine-2-carbonyl)ureido)benzo[d]thiazol-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1416718-31-4 methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(4-(6-(3-(S)-pyrrolidine-2-carbonylureido)benzo[d]thiazol-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate 
• 1416718-15-4 [(S)-1-((S)-2-{5-[4-(6-{3-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-carbonyl]-ureido}-benzothiazol-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester 
• 1280078-93-4 C₂₁H₁₇N₃O₂S 
• 945400-80-6 2-bromanyl-1,3-benzothiazol-6-amine 

Relevant articles and documents

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

METHODS AND MATERIALS FOR INCREASING TRANSCRIPTION FACTOR EB POLYPEPTIDE LEVELS

This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for increasing TFEB polypeptide levels within cells and/or within a nucleus of cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in TFEB polypeptide levels are provided.

Derivatives with uracil-benzothiazole structure, preparation method of derivatives, and application of anti-HCV drugs

According to the invention, a new series of uracil-benzothiazole NS5B RdRp inhibitors are designed and synthesized; the compounds have the structure shown in a general formula (1), wherein the uracil-benzothiazole NS5B RdRp inhibitor provided by the inven